Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 144

1.

Neuroepigenetic signatures of age and sex in the living human brain.

Gilbert TM, Z├╝rcher NR, Catanese MC, Tseng CJ, Di Biase MA, Lyall AE, Hightower BG, Parmar AJ, Bhanot A, Wu CJ, Hibert ML, Kim M, Mahmood U, Stufflebeam SM, Schroeder FA, Wang C, Roffman JL, Holt DJ, Greve DN, Pasternak O, Kubicki M, Wey HY, Hooker JM.

Nat Commun. 2019 Jul 3;10(1):2945. doi: 10.1038/s41467-019-11031-0.

2.

Correction: 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.

Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GA.

Clin Cancer Res. 2019 Feb 15;25(4):1435. doi: 10.1158/1078-0432.CCR-18-4266. No abstract available.

PMID:
30770494
3.

Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer.

Zadra G, Ribeiro CF, Chetta P, Ho Y, Cacciatore S, Gao X, Syamala S, Bango C, Photopoulos C, Huang Y, Tyekucheva S, Bastos DC, Tchaicha J, Lawney B, Uo T, D'Anello L, Csibi A, Kalekar R, Larimer B, Ellis L, Butler LM, Morrissey C, McGovern K, Palombella VJ, Kutok JL, Mahmood U, Bosari S, Adams J, Peluso S, Dehm SM, Plymate SR, Loda M.

Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):631-640. doi: 10.1073/pnas.1808834116. Epub 2018 Dec 21.

4.

The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging.

Larimer BM, Bloch E, Nesti S, Austin EE, Wehrenberg-Klee E, Boland G, Mahmood U.

Clin Cancer Res. 2019 Feb 15;25(4):1196-1205. doi: 10.1158/1078-0432.CCR-18-2407. Epub 2018 Oct 16.

PMID:
30327313
5.

What Can Be Done to Improve Research Biopsy Quality in Oncology Clinical Trials?

Ferry-Galow KV, Datta V, Makhlouf HR, Wright J, Wood BJ, Levy E, Pisano ED, Tam AL, Lee SI, Mahmood U, Rubinstein LV, Doroshow JH, Chen AP.

J Oncol Pract. 2018 Oct 4:JOP1800092. doi: 10.1200/JOP.18.00092. [Epub ahead of print]

PMID:
30285529
6.

The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial.

Andriole GL, Kostakoglu L, Chau A, Duan F, Mahmood U, Mankoff DA, Schuster DM, Siegel BA; LOCATE Study Group.

J Urol. 2019 Feb;201(2):322-331. doi: 10.1016/j.juro.2018.08.050.

PMID:
30179618
7.

Lower Gastrointestinal Tract Applications of PET/Computed Tomography and PET/MR Imaging.

Catalano O, Kilcoyne A, Signore A, Mahmood U, Rosen B.

Radiol Clin North Am. 2018 Sep;56(5):821-834. doi: 10.1016/j.rcl.2018.05.001. Review.

PMID:
30119776
8.

Comparison of the clinical performance of upper abdominal PET/DCE-MRI with and without concurrent respiratory motion correction (MoCo).

Catalano OA, Umutlu L, Fuin N, Hibert ML, Scipioni M, Pedemonte S, Vangel M, Catana AM, Herrmann K, Nensa F, Groshar D, Mahmood U, Rosen BR, Catana C.

Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2147-2154. doi: 10.1007/s00259-018-4084-2. Epub 2018 Jul 11.

PMID:
29998420
9.

Somatostatin receptor type 2 as a radiotheranostic PET reporter gene for oncologic interventions.

Heidari P, Kunawudhi A, Martinez-Quintanilla J, Szretter A, Shah K, Mahmood U.

Theranostics. 2018 May 23;8(12):3380-3391. doi: 10.7150/thno.24017. eCollection 2018.

10.

C11 Methionine PET (MET-PET) Imaging of Glioblastoma for Detecting Postoperative Residual Disease and Response to Chemoradiation Therapy.

Wang Y, Rapalino O, Heidari P, Loeffler J, Shih HA, Oh K, Mahmood U.

Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1024-1028. doi: 10.1016/j.ijrobp.2018.06.011. Epub 2018 Jun 18.

PMID:
29913253
11.

Specific 18F-FDHT Accumulation in Human Prostate Cancer Xenograft Murine Models Is Facilitated by Prebinding to Sex Hormone-Binding Globulin.

Larimer BM, Dubois F, Bloch E, Nesti S, Placzek M, Zadra G, Hooker JM, Loda M, Mahmood U.

J Nucl Med. 2018 Oct;59(10):1538-1543. doi: 10.2967/jnumed.118.208785. Epub 2018 May 31.

PMID:
29853654
12.

The Role of Imaging in Prostate Cancer Care Pathway: Novel Approaches to Urologic Management Challenges Along 10 Imaging Touch Points.

Li Q, Xiang F, Lin X, Grajo JR, Yang L, Xu Y, Duan Y, Vyas U, Harisinghani M, Mahmood U, Samir AE.

Urology. 2018 Sep;119:23-31. doi: 10.1016/j.urology.2018.04.026. Epub 2018 May 3. Review.

PMID:
29730256
13.

Diagnostic performance of PET/MR in the evaluation of active inflammation in Crohn disease.

Catalano OA, Wu V, Mahmood U, Signore A, Vangel M, Soricelli A, Salvatore M, Gervais D, Rosen BR.

Am J Nucl Med Mol Imaging. 2018 Feb 5;8(1):62-69. eCollection 2018.

14.

Radiotheranostics in Cancer Diagnosis and Management.

Jadvar H, Chen X, Cai W, Mahmood U.

Radiology. 2018 Feb;286(2):388-400. doi: 10.1148/radiol.2017170346. Review.

15.

Phage Display Selection, In Vitro Characterization, and Correlative PET Imaging of a Novel HER3 Peptide.

Larimer BM, Phelan N, Wehrenberg-Klee E, Mahmood U.

Mol Imaging Biol. 2018 Apr;20(2):300-308. doi: 10.1007/s11307-017-1106-6.

PMID:
28733706
16.

Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib.

Collier TL, Normandin MD, Stephenson NA, Livni E, Liang SH, Wooten DW, Esfahani SA, Stabin MG, Mahmood U, Chen J, Wang W, Maresca K, Waterhouse RN, El Fakhri G, Richardson P, Vasdev N.

Nat Commun. 2017 Jun 8;8:15761. doi: 10.1038/ncomms15761.

17.

Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast.

Catalano OA, Daye D, Signore A, Iannace C, Vangel M, Luongo A, Catalano M, Filomena M, Mansi L, Soricelli A, Salvatore M, Fuin N, Catana C, Mahmood U, Rosen BR.

Int J Oncol. 2017 Jul;51(1):281-288. doi: 10.3892/ijo.2017.4012. Epub 2017 May 19.

PMID:
28535000
18.

A phase one, single-dose, open-label, clinical safety and PET/MR imaging study of 68Ga-DOTATOC in healthy volunteers.

Esfahani SA, Salcedo S, Heidari P, Catalano OA, Pauplis R, Hesterman J, Kronauge JF, Mahmood U.

Am J Nucl Med Mol Imaging. 2017 Apr 15;7(2):53-62. eCollection 2017.

19.

Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response.

Larimer BM, Wehrenberg-Klee E, Dubois F, Mehta A, Kalomeris T, Flaherty K, Boland G, Mahmood U.

Cancer Res. 2017 May 1;77(9):2318-2327. doi: 10.1158/0008-5472.CAN-16-3346.

20.

PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype.

Catalano OA, Horn GL, Signore A, Iannace C, Lepore M, Vangel M, Luongo A, Catalano M, Lehman C, Salvatore M, Soricelli A, Catana C, Mahmood U, Rosen BR.

Br J Cancer. 2017 Mar 28;116(7):893-902. doi: 10.1038/bjc.2017.26. Epub 2017 Feb 16.

Supplemental Content

Loading ...
Support Center